Association of DCK SNPs with DCK mRNA expression in lymphoblast cell lines from subjects with European (CEPH) and African (YRI) ancestry
Genotype data was not available for Group2Y, Group3Y, and 29377 SNPs in 7, 10, and 1 YRI sample, respectively.
Polymorphism | Phenotype I DCK mRNA Expression | Phenotype II Ara-CTP (nmol/2 × 107 Leukemic Cells | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CEPH (n = 85) | YRI (n = 90) | AML Patients Receiving Ara-C-Continuous Infusion Arm | ||||||||
| Genotype | Mean ± S.D. | Genotype | Mean ± S.D. | Genotype | Mean ± S.D. | |||||
| Group 1/block 1 represented by 3122 C>T | CC (n = 75) | 84 ± 37 | CC (n = 7) | 163 ± 27 | ||||||
| CT (n = 10) | 57 ± 18 | CT (n = 27) | 134 ± 44 | |||||||
| TT (n = 56) | 130 ± 39 | |||||||||
| CC vs. CT, *p = 0.02 | CC vs. CT + TT, *p = 0.04 | |||||||||
| 35708 T>C | TT (n = 75) | 84 ± 37 | TT (n = 6) | 155 ± 44 | TT (n = 18) | 0.48 ± 0.35 | ||||
| CT (n = 10) | 57 ± 18 | CT (n = 27) | 135 ± 41 | CC + CT (n = 9) | 0.22 ± 0.17 | |||||
| CC (n = 57) | 130 ± 18 | |||||||||
| TT vs. CT, *p = 0.02 | TT vs. CT + CC, p = 0.07 | TT vs. CC + CT, *p = 0.04a | ||||||||
| Group 2Y represented by 3547C>T and linked to A119G | CC (n = 80) | 136 ± 41 | ||||||||
| CT (n = 3) | 170 ± 47 | |||||||||
| CC vs. CT, p = 0.16 (0.08b) | ||||||||||
| Group 3Y represented by 36113C>T | CC (n = 75) | 141 ± 41 | ||||||||
| CT (n = 5) | 97 ± 22 | |||||||||
| CC vs. CT, *p = 0.01 | ||||||||||
| -245 G>C | GG (n = 85) | 138 ± 42 | ||||||||
| GC (n = 5) | 95 ± 26 | |||||||||
| GG vs. GC, *p = 0.01 | ||||||||||
| 29377 C>T | CC (n = 86) | 138 ± 41 | ||||||||
| CT (n = 3) | 85 ± 6 | |||||||||
|
|
|
| CC vs. CT, *p = 0.03 |
|
| |||||